Status:
COMPLETED
Ultrasound-assisted vs Landmark Based Intrathecal Administration of Nusinersen
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Muscular Atrophy, Spinal
Ultrasound
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Intrathecal administration of Nusinersen, an antisense oligonucleotide capable of increasing Survival Motor Neuron protein production, has been tested in Spinal Muscular Atrophy (SMA) to improve motor...
Detailed Description
Background Nusinersen, an antisense oligonucleotide (ASO) capable of increasing SMN protein production, has been used in clinical trials in infants and children with SMA type 1 or type 2 and has been ...
Eligibility Criteria
Inclusion
- SMA adult patients
Exclusion
- coagulation defects;
- medication with anticoagulant;
- infection in puncture site;
- high intracranial pressure
Key Trial Info
Start Date :
December 14 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 21 2023
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT04674618
Start Date
December 14 2020
End Date
December 21 2023
Last Update
February 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Policlinico Agostino Gemelli
Rome, Italy, 00168